Macroeconomic headwinds and recessionary concerns will not weaken healthcare deals next year after the market experienced resilient mergers and acquisitions in 2022.
Contract drugmaker Emergent Biosolutions said on Tuesday its over-the-counter naloxone-based nasal spray as a treatment for suspected opioid overdose would be reviewed on a priority basis by the FDA.
Contract drugmaker Emergent Biosolutions said on Tuesday its over-the-counter nasal spray as a treatment for suspected opioid overdose would be reviewed on a…